Hypoxia-inducible gene expression system using the erythropoietin enhancer and 3′-untranslated region for the VEGF gene therapy

Journal of Controlled Release

Volumn 115, Issue 1, 2006, Pages 113-119

  Lee, Minhyung ^a   Choi, Donghoon ^b   Choi, Min Ji ^a   Jeong, Ji Hoon ^c   Kim, Won Jong ^c   Oh, Seungjoon ^d   Kim, Yong Hee ^a   Bull, David A ^e   Kim, Sung Wan ^c  

^a Hanyang University   (South Korea)

^b Yonsei University   (South Korea)

^c UNIVERSITY OF UTAH   (United States)

^d Kyung Hee University Hospital   (South Korea)

^e UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

3 Untranslated region; Erythropoietin enhancer; Gene therapy; Hypoxia; Ischemic disease; Vascular endothelial growth factor

Indexed keywords

DISEASES; GROWTH KINETICS; PROTEINS; TUMORS;

′-UNTRANSLATED REGION; ERYTHROPOIETIN ENHANCERS; GENE THERAPY; HYPOXIA; ISCHEMIC DISEASE; VASCULAR ENDOTHELIAL GROWTH FACTOR;

GENES;

ERYTHROPOIETIN; LUCIFERASE; POLYETHYLENEIMINE; VASCULOTROPIN;

3' UNTRANSLATED REGION; ANIMAL CELL; ARTICLE; CELL HYPOXIA; EMBRYO; ENHANCER REGION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE THERAPY; HUMAN; HUMAN CELL; HYPOXIA; ISCHEMIA; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; RAT;

3' UNTRANSLATED REGIONS; ANIMALS; ANOXIA; CELL LINE; CLONING, MOLECULAR; ENHANCER ELEMENTS (GENETICS); ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROPOIETIN; GENE EXPRESSION; GENE THERAPY; HUMANS; LUCIFERASES; PLASMIDS; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33748788239     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2006.07.010     Document Type: Article

References (43)

1. Takeshita S., Zheng L.P., Brogi E., Kearney M., Pu L.Q., Bunting S., Ferrara N., Symes J.F., and Isner J.M. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J. Clin. Invest. 93 (1994) 662-670
2. Isner J.M. Myocardial gene therapy. Nature 415 (2002) 234-239
3. Isner J.M., Walsh K., Symes J., Pieczek A., Takeshita S., Lowry J., Rosenfield K., Weir L., Brogi E., and Jurayj D. Arterial gene transfer for therapeutic angiogenesis in patients with peripheral artery disease. Hum. Gene Ther. 7 (1996) 959-988
4. Azrin M. Angiogenesis, protein and gene delivery. Br. Med. Bull. 59 (2001) 211-225
5. Kutryk M.J., and Stewart D.J. Angiogenesis of the heart. Microsc. Res. Tech. 60 (2003) 138-158
6. Brogi E., Schatteman G., Wu T., Kim E.A., Varticovski L., Keyt B., and Isner J.M. Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression. J. Clin. Invest. 97 (1996) 469-476
7. Lee J.S., and Feldman A.M. Gene therapy for therapeutic myocardial angiogenesis: a promising synthesis of two emerging technologies. Nat. Med. 4 (1998) 739-742
8. Springer M.L., Chen A.S., Kraft P.E., Bednarski M., and Blau H.M. VEGF gene delivery to muscle: potential role for vasculogenesis in adults. Mol. Cell 2 (1998) 549-558
9. Lee R.J., Springer M.L., Blanco-Bose W.E., Shaw R., Ursell P.C., and Blau H.M. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 102 (2000) 898-901
10. Shibata T., Akiyama N., Noda M., Sasai K., and Hiraoka M. Enhancement of gene expression under hypoxic conditions using fragments of the human vascular endothelial growth factor and the erythropoietin genes. Int. J. Radiat. Oncol. Biol. Phys. 42 (1998) 913-916
11. Binley K., Iqball S., Kingsman A., Kingsman S., and Naylor S. An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer. Gene Ther. 6 (1999) 1721-1727
12. Shibata T., Giaccia A.J., and Brown J.M. Development of a hypoxia-responsive vector for tumor-specific gene therapy. Gene Ther. 7 (2000) 493-498
13. Koshikawa N., Takenaga K., Tagawa M., and Sakiyama S. Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells. Cancer Res. 60 (2000) 2936-2941
14. Modlich U., Pugh C.W., and Bicknell R. Increasing endothelial cell specific expression by the use of heterologous hypoxic and cytokine-inducible enhancers. Gene Ther. 7 (2000) 896-902
15. Tang Y., Jackson M., Qian K., and Phillips M.I. Hypoxia inducible double plasmid system for myocardial ischemia gene therapy. Hypertension 39 (2002) 695-698
16. Su H., Arakawa-Hoyt J., and Kan Y.W. Adeno-associated viral vector-mediated hypoxia response element-regulated gene expression in mouse ischemic heart model. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 9480-9485
17. Binley K., Askham Z., Martin L., Spearman H., Day D., Kingsman S., and Naylor S. Hypoxia-mediated tumour targeting. Gene Ther. 10 (2003) 540-549
18. Lee M., Rentz J., Bikram M., Han S., Bull D.A., and Kim S.W. Hypoxia-inducible VEGF gene delivery to ischemic myocardium using water-soluble lipopolymer. Gene Ther. 10 (2003) 1535-1542
19. Lee M., Bikram M., Oh S., Bull D.A., and Kim S.W. Sp1-dependent regulation of the RTP801 promoter and its application to hypoxia-inducible VEGF plasmid for ischemic disease. Pharm. Res. 21 (2004) 736-741
20. Lee M., Lee E.S., Kim Y.S., Choi B.H., Park S.R., Park H.S., Park H.C., Kim S.W., and Ha Y. Ischemic injury-specific gene expression in the rat spinal cord injury model using hypoxia-inducible system. Spine 30 (2005) 2729-2734
21. Rondon I.J., MacMillan L.A., Beckman B.S., Goldberg M.A., Schneider T., Bunn H.F., and Malter J.S. Hypoxia up-regulates the activity of a novel erythropoietin mRNA binding protein. J. Biol. Chem. 266 (1991) 16594-16598
22. McGary E.C., Rondon I.J., and Beckman B.S. Post-transcriptional regulation of erythropoietin mRNA stability by erythropoietin mRNA-binding protein. J. Biol. Chem. 272 (1997) 8628-8634
23. Maxwell P.H., Pugh C.W., and Ratcliffe P.J. Inducible operation of the erythropoietin 3′ enhancer in multiple cell lines: evidence for a widespread oxygen-sensing mechanism. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 2423-2427
24. Jiang B.H., Rue E., Wang G.L., Roe R., and Semenza G.L. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J. Biol. Chem. 271 (1996) 17771-17778
25. Wang G.L., and Semenza G.L. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 4304-4308
26. Kim Y.H., Park J.H., Lee M., Kim Y.H., Park T.G., and Kim S.W. Polyethylenimine with acid-labile linkages as a biodegradable gene carrier. J. Control. Release 103 (2005) 209-219
27. Kunath K., von Harpe A., Fischer D., Petersen H., Bickel U., Voigt K., and Kissel T. Low-molecular-weight polyethylenimine as a non-viral vector for DNA delivery: comparison of physicochemical properties, transfection efficiency and in vivo distribution with high-molecular-weight polyethylenimine. J. Control. Release 89 (2003) 113-125
28. Jeong J.H., Lee M., Kim W.J., Yockman J.W., Park T.G., Kim Y.H., and Kim S.W. Anti-GAD antibody targeted non-viral gene delivery to islet beta cells. J. Control. Release 107 (2005) 562-570
29. Kim W.J., Yockman J.W., Lee M., Jeong J.H., Kim Y.H., and Kim S.W. Soluble Flt-1 gene delivery using PEI-g-PEG-RGD conjugate for anti-angiogenesis. J. Control. Release 106 (2005) 224-234
30. Kang H.C., Kim S., Lee M., and Bae Y.H. Polymeric gene carrier for insulin secreting cells: poly(l-lysine)-g-sulfonylurea for receptor mediated transfection. J. Control. Release 105 (2005) 164-176
31. Bikram M., Lee M., Chang C.W., Janat-Amsbury M.M., Kern S.E., and Kim S.W. Long-circulating DNA-complexed biodegradable multiblock copolymers for gene delivery: degradation profiles and evidence of dysopsonization. J. Control. Release 103 (2005) 221-233
32. Sanchez-Elsner T., Botella L.M., Velasco B., Langa C., and Bernabeu C. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J. Biol. Chem. 277 (2002) 43799-43808
33. Lee M., Song S.U., Ryu J.K., and Suh J.K. Sp1-dependent regulation of the tissue inhibitor of metalloproteinases-1 promoter. J. Cell. Biochem. 91 (2004) 1260-1268
34. Phillips M.I., Tang Y., Schmidt-Ott K., Qian K., and Kagiyama S. Vigilant vector: heart-specific promoter in an adeno-associated virus vector for cardioprotection. Hypertension 39 (2002) 651-655
35. Choi D., Lee M., Bull D.A., Reiss R., Chang C.W., Christensen L., and Kim S.W. Hypoxia-inducible VEGF gene therapy using the RTP801 promoter. Molec. Ther. 9 (2004) S74-S75
36. Ido A., Uto H., Moriuchi A., Nagata K., Onaga Y., Onaga M., Hori T., Hirono S., Hayashi K., Tamaoki T., and Tsubouchi H. Gene therapy targeting for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to a human alpha-fetoprotein promoter. Cancer Res. 61 (2001) 3016-3021
37. Hernandez-Alcoceba R., Pihalja M., Nunez G., and Clarke M.F. Evaluation of a new dual-specificity promoter for selective induction of apoptosis in breast cancer cells. Cancer Gene Ther. 8 (2001) 298-307
38. Shibata T., Giaccia A.J., and Brown J.M. Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy. Neoplasia 4 (2002) 40-48
39. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev., Cancer 3 (2003) 721-732
40. Tillmar L., and Welsh N. Hypoxia may increase rat insulin mRNA levels by promoting binding of the polypyrimidine tract-binding protein (PTB) to the pyrimidine-rich insulin mRNA 3'-untranslated region. Mol. Med. 8 (2002) 263-272
41. Scandurro A.B., and Beckman B.S. Common proteins bind mRNAs encoding erythropoietin, tyrosine hydroxylase, and vascular endothelial growth factor. Biochem. Biophys. Res. Commun. 246 (1998) 436-440
42. Levy A.P., Levy N.S., and Goldberg M.A. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J. Biol. Chem. 271 (1996) 2746-2753
43. Gorlach A., Camenisch G., Kvietikova I., Vogt L., Wenger R.H., and Gassmann M. Efficient translation of mouse hypoxia-inducible factor-1alpha under normoxic and hypoxic conditions. Biochim. Biophys. Acta 1493 (2000) 125-134